Subcellular localization of accumulated p53 in ovarian cancer cells

Gynecologic Oncology

Volumn 61, Issue 2, 1996, Pages 266-271

  Runnebaum, Ingo B ^b   Kieback, Dirk G ^a,b   Möbus, Volker J ^b   Tong, Xiao Wen ^b   Kreienberg, Rolf ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0029966595     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0137     Document Type: Article

References (41)

1. Montenarh, M. Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53, Crit. Rev. Oncogen. 3, 233-256 (1992).
2. Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke-Pearson, D., Iglehart, J. D., Bast, R. C. J., and Berchuck, A. Overexpression and mutation of p53 in epithelial ovarian cancer, Cancer Res. 51, 2979-2984 (1991).
3. Okamoto, A., Sameshima, Y., Yokoyama, S., Terashima, Y., Sugimura, T., Terada, M., and Yokota, J. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer, Cancer Res. 51, 5171-5176 (1991).
4. Tsao, S. W., Mok, C. H., Oike, K., Muto, M., Goodman, H. M., Sheets, E. E., Berkowitz, R. S., Knapp, R. C., and Lau, C. C. Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors, Anticancer Res. 11, 1975-1982 (1991).
5. Kupryjanczyk, J., Thor, A. D., Beauchamp, R., Merritt, V., Edgerton, S. M., Bell, D. A., and Yandell, D. W. p53 gene mutations and protein accumulation in human ovarian cancer, Proc. Natl. Acad. Sci. USA 90, 4961-4965 (1993).
6. Milner, B. J., Allan, L. A., Eccles, D. M., Kitchener, H. C., Leonard, R. C. F., Kelly, K. F., Parkin, D. E., and Haites, N. E. p53 Mutation is a common genetic event in ovarian carcinoma, Cancer Res. 53, 2128-2132 (1993).
7. Runnebaum, I. B., Tong, X. W., König, R., Hong, Z., Körner, K., Atkinson, E. N., Kreienberg, R., and Kieback, D. G. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer, Lancet 345, 994 (1995).
8. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi, K. O., and Oren, M. Wild-type p53 can inhibit oncogene-mediated focus formation, Proc. Natl. Acad. Sci. USA 86, 8763-8767 (1989).
9. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53, Science 249, 912-915 (1990).
10. Cheng, J., Yee, J. K., Yeargin, J., Friedmann, T., and Haas, M. Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene, Cancer Res. 52, 222-226 (1992).
11. Runnebaum, I. B., Yee, J.-K., Kieback, D. G., Sukumar, S., and Friedmann, T. Wild-type p53 suppresses the malignant phenotype in breast cancer cells containing mutant p53 alleles, Anticancer Res. 14, 1137-1144 (1994).
12. Runnebaum, I. B., and Kreienberg, R. p53 trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: An expeditious in vitro protocol with implications towards gene therapy, Hybidoma 14, 153-157 (1995).
13. Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., and Vogelstein, B. Identification of p53 as a sequence-specific DNA-binding protein, Science 252, 1708-1711 (1991).
14. Unger, T., Nau, M. M., Segal, S., and Minna, J. D. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer, Embo J. 11, 1383-1390 (1992).
15. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage, Cancer Res. 51, 6304-6311 (1991).
16. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J. J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia, Cell 71, 587-597 (1992).
17. Lowe, S. W., and Ruley, H. E. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis, Genes Dev. 7, 535-545 (1993).
18. Yonish-Rouach, E., Grunwald, D., Wilder, S., Kimchi, A., May, E., Lawrence, J.-J., May, P., and Oren, M. p53-mediated cell death: Relationship to cell cycle control, Mol. Cell. Biol. 13, 1415-1423 (1993).
19. Runnebaum, I. B., Wang, S., and Kreienberg, R. Retrovirally mediated wild-type p53 restores S phase modulation without inducing WAF1 mRNA in breast carcinoma cells containing mutant p53, J. Cell Biochem. 59, 538-544 (1995).
20. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations, Science 265, 346-355 (1994).
21. Moll, U. M., Riou, G., and Levine, A. J. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion, Proc. Natl. Acad. Sci USA 89, 7262-7266 (1992).
22. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer, Lancet 335, 675-679 (1990).
23. Ali, I. U., Schweitzer, J. B., Ikejiri, B., Saxena, A., Robertson, J. T., and Oldfield, E. H. Heterogeneity of subcellular localization of p53 in human glioblastomas, Cancer Res. 54, 1-5 (1994).
24. Moll, U. M., LaQuaglia, M., Benard, J., and Riou, G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors, Proc. Natl. Acad. Sci. USA 92, 4407-4411 (1995).
25. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas, Nature 358, 80-83 (1992).
26. Lin, J., Chen, J., Elenbaas, B., and Levine, A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein, Genes Dev. 8, 1235-1246 (1994).
27. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, Nature 362, 857-860 (1993).
28. Runnebaum, I. B., Tong, X.-W., Moebus, V., Heilmann, V., Kieback, D. G., and Kreienberg, R. Multiplex PCR (MPCR) screening detects small p53 deletions and insertions in human ovarian cancer cell lines, Hum. Genet. 93, 620-624 (1994).
29. Jacobs, I. J., Kohler, M. F., Wiseman, R. W., Marks, J. R., Whitaker, R., Kerns, B. A., Humphrey, P., Berchuck, A., Ponder, B. A., and Bast, R. C. J. Clonal origin of epithelial ovarian carcinoma: Analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation, J. Natl. Cancer Inst. 84, 1793-1798 (1992).
30. Bosari, S., Giuseppe, V., Radaelli, U., Bossi, P., Bonoldi, E., and Coggi, G. p53 accumulation in ovarian carcinomas and its prognostic implications, Hum. Pathol. 24, 1175-1179 (1993).
31. Hartmann, L. C., Podratz, K. C., Keeney, G. L., Kamel, N. A., Edmonson, J. H., Grill, J. P., Su, J. Q., Katzmann, J. A., and Roche, P. C. Prognostic significance of p53 immunostaining in epithelial ovarian cancer, J. Clin. Oncol. 12, 64-69 (1994).
32. Moebus, V., Gerharz, C. D., Press, U., Moll, R., Beck, T., Mellin, W., Pollow, K., Knapstein, P. G., and Kreienberg, R. Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines, Int. J. Cancer 52, 76-84 (1992).
33. Sheikh, M. S., Shao, Z.-M., Hussain, A., and Fontana, J. A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma, Cancer Res. 53, 3226-3228 (1993).
34. Runnebaum, I. B., Tong, X.-W., Möbus, V. J., Kieback, D. G., Rosenthal, H. E., and Kreienberg, R. p53 mutant His175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6, FEBS Lett. 353, 29-32 (1994).
35. Remmele, W., and Stegner, H. E. Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (1RS) für den immunhistochemischen Östrogenrezeptor-Nachweis, Pathologe 8, 138-140 (1987).
36. Runnebaum, I. B., Syka, P., and Sukumar, S. Vector PCR, BioTechniques 11, 446-454 (1991).
37. Runnebaum, I.B., Nagarajan, M., Bowman, M., Soto, D., and Sukumar, S. Mutations in p53 as potential molecular markers for human breast cancer, Proc. Natl. Acad. Sci. USA 88, 10657-10661 (1991).
38. Shaulsky, G., Goldfinger, N., Ben, Z. A., and Rotter, V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis, Mol. Cell. Biol. 10, 6565-6577 (1990).
39. Shaulsky, G., Goldfinger, N., Tosky, M. S., Levine, A. J., and Rotter, V. Nuclear localization is essential for the activity of p53 protein, Oncogene 6, 2055-2065 (1991).
40. Runnebaum, I. B., Maier, S., Tong, X.-W., Rosenthal, H. E., Möbus, V. J., Kieback, D. G., and Kreienberg, R. Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in German patients, Cancer Epidem. Biomar. 4, 573-575 (1995).
41. Srinivasan, R., Roth, J. A., and Maxwell, S. A. Sequence-specific interaction of a conformational domain of p53 with DNA, Cancer Res. 53, 5361-5364 (1993).